Roivant dis­con­tin­ues blood can­cer pro­gram as it fails to re­vive old Ei­sai drug, to dis­solve Hema­vant

Roivant dis­closed Tues­day morn­ing that it has stopped work on a treat­ment for myelodys­plas­tic syn­dromes, a pre­cur­sor dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.